CAR T-Cell
Immunotherapy

How CAR T-Cell
Immunotherapy Works

In its essence, CAR T-Cell Immunotherapy utilises the body’s
natural defences to fight cancer. It does this in the following ways:

In its essence, CAR T-Cell Immunotherapy utilises the body’s natural defences to fight cancer. It does this in the following ways:

https://immunotherapy.life/wp-content/uploads/2021/01/Icon-1-1.png

Helping the immune system
work better at finding and
destroying cancer cells.

https://immunotherapy.life/wp-content/uploads/2021/01/Icon-2-2.png

Stopping or slowing the
growth of cancer cells
in the body.

https://immunotherapy.life/wp-content/uploads/2021/01/Icon-3.png

Stopping or slowing the
spread of cancer cells
around the body.

https://immunotherapy.life/wp-content/uploads/2021/01/Icon-4-1.png

Prolonging remissions
as CAR T-Cells can persist
in the body.

Slide 01
Slide 02
Diagram-CART-Immunotheraphy-01-Mobile copy
Diagram-CART-Immunotheraphy-02-Mobile copy

An array of non-CAR T-Cell products are also available under the Other Immunotherapy category.

Available CAR T-Cell
Immunotherapy Gene Products

IMMUNOTHERAPY GENE PRODUCT TYPE OF CANCER
IL13Rα2
  • Glioma / Glioblastoma Multiforme
Claudin18.2
  • Gastric
  • Pancreatic
Mesothelin
  • Mesothelioma
  • Pancreatic
  • Ovarian
GPC3
  • Liver
PSMA
  • Prostate

An array of non-CAR T-Cell products are also available under the Other Immunotherapy category.

The Treatment Process

Pre-Assessment

Doctor consults patient and assess their health to determine suitability for treatment.

Collection

Blood is collected from patient at a medical centre and sent to the laboratory for CAR T-Cell production.

Screenshot 2021-01-23 at 6.42.51 PM

Treatment

Patient is treated with an infusion of CAR T-Cells.

Post-Monitoring

Medical follow up or biopsy is performed on the patient to monitor progress.

STATISTICS

The Numbers Behind
CAR T-Cell Immunotherapy

The coverage area for CAR T-Cell Immunotherapy is expanding, and that means even more reasons not to give up.

THERAPEUTIC AREA

Haematological Cancer

Solid Tumour

T-Cell Immunotherapies: Development Pipeline

Distribution by Indication

https://immunotherapy.life/wp-content/uploads/2021/01/Untitled-1.jpg

As reported by the Global T-cell (CAR-T, TCR, TIL) Therapy Market (5th Edition), 2020-2030

https://immunotherapy.life/wp-content/uploads/2021/02/0001-320x454.jpg

For a more in-depth understanding on
CAR T-Cell Immunotherapy, we’ve
prepared a brochure that provides you
with the information you need.

For a more in-depth understanding on CAR T-Cell Immunotherapy, we’ve prepared a brochure that provides you with the information you need.

Have Any Questions About CAR T-Cell
Immunotherapy That Isn’t Listed On Our FAQ Page?
Reach Out To Us And We’ll Get In Touch.

COMPANY

Sign up for you and your loved ones to receive the latest news and updates about CAR T-Cell Immunotherapy.

    https://immunotherapy.life/wp-content/uploads/2021/02/MGRC-LogoFooter.png
    https://immunotherapy.life/wp-content/uploads/2021/01/MGRC-Logo.png
    https://immunotherapy.life/wp-content/uploads/2021/02/Cyterium-Logo-RGB-02-320x68.png
    https://immunotherapy.life/wp-content/uploads/2021/01/MGRC-Logo.png

    Copyright © 2021 Malaysian Genomics Resource Centre Berhad (652790-V). All Rights Reserved.

    Copyright © 2021 Malaysian Genomics Resource Centre Berhad (652790-V). All Rights Reserved.